Featured content
AI builds dual-action cancer drug targeting PKMYT1
2026-04-07T15:17:00+01:00By Drug Target Review
New research published in Nature Communications shows how generative AI can be used to design complex dual-action cancer drug candidates. Insilico Medicine has developed a PKMYT1 degrader that both eliminates the target protein and blocks its activity, demonstrating the growing role of AI in advanced drug discovery.
Improving selectivity in antibody–drug conjugates
2026-04-06T10:00:00+01:00By Sam Wightwick (Drug Target Review)
Promatix Biosciences is developing a new generation of bispecific antibody–drug conjugates using proprietary membrane proteomics data to identify highly selective target pairings. CEO Dr Michael Hunter explains how the company’s TXPro database enables discovery of previously unexplored tumour biology to improve therapeutic index and reduce on-target/off-tumour toxicities in solid tumours.